Company
Calico
Calico is an Alphabet-founded biotechnology research company focused on understanding the biology of human aging and developing therapeutic interventions for age-related diseases. The company conducts fundamental aging research, builds technologies to study aging biology at scale, and operates a drug-development pipeline targeting conditions including polycystic kidney disease. Based in South San Francisco, Calico combines internal innovation labs with academic and industry partnerships.
Calico is a privately held company operating in the biotechnology, ageing and health care sectors, based in the United States.
Leadership
Former
Recent developments
AI summary of recent coverageRecent coverage has focused on Calico Life Sciences' regulatory progress for multiple investigational treatments, including breakthrough therapy designation for fosigotifator in vanishing white matter disease and orphan drug and fast track designations for an anti-PAPP-A antibody candidate for autosomal dominant polycystic kidney disease. The company has also made executive appointments in its drug discovery leadership.
Summarized from the headlines in the sidebar; see each source for the full story.